Resources
11 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 1/20/2021 (updated 4/4/2024)
People who use drugs (PWUD) in the U.S. experience disproportionate adverse health outcomes and mortality as compared with the population as a whole (Lake & Kennedy, 2016; Reisinger, Pratt, Shoenborn, & Druss, 2017). Similar health outcomes have been reported elsewhere, for example in the UK (Neale, 2004), and across 8 other European countries (Bargagli et al., 2006). In the U.S. health outcomes among PWUD are intensified by the overdose pandemic, epidemic rates of HIV, hepatitis A and C, skin and soft tissue infections (CDC Centers for Disease Control and Prevention, 2020; Hagen, Thiede, & Des Jarlais, 2005; Scholl, Seth, Kariisa, Wilson, & Baldwin, 2019), and by structural barriers thwarting health access and utilization.
Posted 12/29/2020 (updated 4/4/2024)
An analysis of emergency department data shows a rise in nonfatal drug overdoses for youth under 15, from 2016 to 2019. Overdoses among the youngest kids aged 0-14 are relatively rate. However, risk increases with age, as the rate of all drug overdoses among youth aged 15-24 was more than double that of 11-14-year olds. Stimulant overdoses increased for all age groups, while heroin decreased for 15-24-year olds.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 12/23/2020 (updated 4/4/2024)
This article presents an important look into stigma of families impacted by NAS and the ways in which healthcare providers must work to combat stigma’s harmful effects, and explores directions for future research of strategies for reducing stigma amongst this population to improve engagement in healthcare and positive heath-seeking behaviors. The authors reported that mothers of infants with NAS experience intensified stigma surrounding SUDs and the challenge of overcoming exclusion, shame, and judgement of their ability to parent. In examining nurses’ perceptions of perinatal women with SUD, the authors found that many struggled with negative attitudes and prejudices towards mothers of infants with NAS that interfered with their ability to provide nonjudgmental care. The authors urge nurses to implement substantial strategies for addressing stigma through tools such as the ACTS script.
Posted 7/28/2021 (updated 4/2/2024)
Public health professionals refer to “hard to reach populations” as those who are not likely to access traditional health care and social services on their own due to various barriers that may include mental illness, unstable housing, lack of transportation, and substance use disorders (SUDs). Stigma and trust issues may play a role in those with SUD not seeking out services.
Posted 9/30/2020 (updated 3/29/2024)
This page offers background information and tips for providers to keep in mind while using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.
Posted 4/26/2022 (updated 3/27/2024)
Background: The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programmes, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).
Posted 6/27/2022 (updated 3/27/2024)
Naloxone leave behind programs are a popular public health intervention for combatting the opioid epidemic. These programs are designed for first responders to educate and equip high risk, nonmedical individuals to respond to opioid overdose scenarios. However, stigma and misconceptions regarding naloxone remain common among medical providers, including emergency medical services (EMS) members.
Posted 3/23/2022 (updated 3/27/2024)
Over the past 20 years, drug overdose deaths have increased dramatically in the United States. Most of these deaths involved opioids, including prescription pain medications, heroin, and synthetic opioids such as fentanyl. These are called opioid-related overdoses and often occur as a result of respiratory depression caused by opioids, even when other medications and drugs are involved.